BioAge Labs (NASDAQ:BIOA) today reported its financial results for the full year ended December 31, 2025, marking a pivotal transition from early-stage discovery to a high-conviction clinical platform.
The company’s primary catalyst was the announcement of positive interim Phase 1 data for BGE-102, its potent, orally bioavailable NLRP3 inhibitor.
In the study, BGE-102 demonstrated a 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at the 120 mg dose level, signaling powerful target engagement and a potentially best-in-class anti-inflammatory profile.
The NLRP3 inflammasome is a key driver of chronic inflammation associated with aging and metabolic diseases.
By achieving such a dramatic reduction in hsCRP—a validated systemic inflammatory marker—BioAge has cleared a significant hurdle for the program's advancement.
The company confirmed it is on track to initiate a Phase 2a clinical trial in the first half of 2026, which will further evaluate the candidate’s efficacy in treating inflammatory and age-related pathologies.
Financially, BioAge has solidified its position as one of the most well-capitalized longevity-focused biotechs on the market.
Following a successful, upsized follow-on offering that raised $132.3 million, the company reported $285.1 million in cash and marketable securities as of December 31, 2025.
This robust balance sheet provides an exceptionally long operational runway, with management estimating that current funds are sufficient to support R&D and capital expenditures through 2029.